fidexaban has been researched along with Blood Clot in 4 studies
Fidexaban: structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arterial thrombus formation was measured in Badimon Chamber at baseline, end-of-infusion [EoI], and four hours and eight hours after EoI, and factor-X activity, prothrombin time [PT] ratio and plasma drug levels were measured simultaneously." | 2.73 | Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. ( Chesebro, JH; Crook, J; Farkouh, ME; Fuster, V; Leadley, R; Osende, J; Palencia, S; Shimbo, D; Zafar, MU, 2007) |
| "The time to formation of an occlusive thrombus in the femoral arteries averaged 69+/-5 min in the control group compared to 127+/-19, 192+/-33 and 219+/-15 min in the low-, mid- and high-dose CI-1031 groups." | 1.31 | The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. ( Hicks, GW; Janiczek-Dolphin, N; Juneau, PL; Leadley, R; McClanahan, TB; Mertz, TE; Morrison, AL; Morser, J; Peng, YW; Sullivan, ME, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pinto, DJ | 1 |
| Smallheer, JM | 1 |
| Cheney, DL | 1 |
| Knabb, RM | 1 |
| Wexler, RR | 1 |
| Karnicki, K | 1 |
| McBane, RD | 1 |
| Miller, RS | 1 |
| Leadley, RJ | 1 |
| Morser, J | 2 |
| Owen, WG | 1 |
| Chesebro, JH | 2 |
| Zafar, MU | 1 |
| Farkouh, ME | 1 |
| Osende, J | 1 |
| Shimbo, D | 1 |
| Palencia, S | 1 |
| Crook, J | 1 |
| Leadley, R | 2 |
| Fuster, V | 1 |
| McClanahan, TB | 1 |
| Hicks, GW | 1 |
| Morrison, AL | 1 |
| Peng, YW | 1 |
| Janiczek-Dolphin, N | 1 |
| Mertz, TE | 1 |
| Sullivan, ME | 1 |
| Juneau, PL | 1 |
1 review available for fidexaban and Blood Clot
| Article | Year |
|---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Dr | 2010 |
1 trial available for fidexaban and Blood Clot
| Article | Year |
|---|---|
Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Topics: Amidines; Animals; Aorta; Blood Coagulation; Coronary Artery Disease; Dose-Response Relationship, Dr | 2007 |
2 other studies available for fidexaban and Blood Clot
| Article | Year |
|---|---|
Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Topics: Amidines; Animals; Anticoagulants; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Dos | 2004 |
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
Topics: Amidines; Animals; Anticoagulants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; E | 2001 |